Tysabri and Progressive Multifocal Leukoencephalopathy: What Arizona Patients Should Know
From General Health Information to Targeted Risk Awareness
If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding the link to progressive multifocal leukoencephalopathy (PML) is critical. Decades of pharmacovigilance have established that while PML is rare, prompt diagnosis and monitoring can significantly affect outcomes. This page reviews published evidence on Tysabri-associated PML, including risk factors, diagnostic approaches, and follow-up protocols.
Understanding Tysabri and Its Association with PML
Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri-treated patients have developed this condition even in the absence of other immunosuppressive factors. Three risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, visual changes, and speech difficulties. In the FDA Adverse Event Reporting System (FAERS) database, adverse events most frequently associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and depression (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports are not specific to PML, they reflect the range of neurological symptoms that may be observed in patients on Tysabri and that could overlap with early PML manifestations.
The TOUCH Prescribing Program and Monitoring Requirements
Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program requires that prescribers evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Prescribers must determine every six months whether patients should continue treatment and, if so, authorize treatment for another six months. They must also submit a "TYSABRI Patient Status Report and Reauthorization Questionnaire" six months after initiating treatment and every six months thereafter. When Tysabri is discontinued, an "Initial Discontinuation Questionnaire" and a "6-Month Discontinuation Questionnaire" must be completed. Cases of PML, hospitalizations due to opportunistic infections, and deaths must be reported to Biogen at 1-800-456-2255 as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Statute of Limitations for Tysabri Claims in Arizona
For patients in Arizona who have developed PML after Tysabri exposure, the statute of limitations for filing a legal claim is a critical consideration. The statute of limitations is a time limit within which a lawsuit must be filed. In Arizona, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. For claims involving wrongful death, the statute of limitations is also two years from the date of death. However, the specific timeline may vary depending on the circumstances of the case, such as when the patient or their family became aware of the link between Tysabri and PML. The timeline between Tysabri exposure and documented harm is relevant to statute of limitations calculations. PML can develop months to years after starting Tysabri, with risk increasing after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The onset of symptoms may be gradual, and diagnosis can be delayed. The statute of limitations clock typically starts when the injury is discovered or when a reasonable person would have discovered it. For PML, this could be the date of diagnosis or the date when symptoms first appeared and were linked to Tysabri.
Settlement Considerations and Legal Recourse
Settlement considerations for affected patients may include the adequacy of warnings provided by the manufacturer. The boxed warning clearly states that Tysabri increases the risk of PML and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, patients may argue that the warnings were insufficient or that the risks were not adequately communicated to them or their healthcare providers. The TOUCH program is designed to ensure that patients are informed of the risks, but compliance with the program does not necessarily eliminate liability if a patient develops PML. Patients who have developed PML after Tysabri treatment may be eligible for compensation through a settlement or lawsuit. The settlement amount may depend on factors such as the severity of the injury, the patient's age, the impact on quality of life, medical expenses, lost wages, and pain and suffering. In some cases, a global settlement may be reached for a group of affected patients, while in others, individual claims may be pursued. It is important for patients and their families to consult with a legal professional experienced in pharmaceutical litigation to understand their rights and the applicable statute of limitations in Arizona. The two-year window from discovery of the injury is a strict deadline, and failure to file within that time may bar recovery. Given the complexity of PML diagnosis and the potential for delayed recognition, early legal consultation is advisable.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri-related PML claims in Arizona?
In Arizona, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or reasonably should have been discovered. For wrongful death claims, it is also two years from the date of death. It is crucial to consult with an attorney to determine the exact deadline based on your specific circumstances.
What are the risk factors for developing PML while on Tysabri?
Three risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing Tysabri treatment.
What is the TOUCH Prescribing Program?
The TOUCH Prescribing Program is a restricted distribution program for Tysabri designed to manage the risk of PML. It requires prescribers to evaluate patients at specified intervals, submit status reports, and report any cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen at 1-800-456-2255 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.